MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

PHASE3CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

October 26, 2018

Primary Completion Date

March 5, 2020

Study Completion Date

January 22, 2021

Conditions
Glabellar LinesLateral Canthal Lines
Interventions
DRUG

MT10109L

MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.

DRUG

Placebo

Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.

Trial Locations (21)

10016

Laser & Skin Surgery Center of New York, New York

10707

RZANY & HUND - Privatpraxis fur Dermatologie und Asthetische Medizin, Berlin

21030

MD Laser, Skin, & Vein Institute, Hunt Valley

22209

SkinDC, Arlington

23502

Virginia Clinical Research, Inc., Norfolk

33146

Skin Research Institute LLC, Coral Gables

34121

DRK-Kliniken Nordhessen, Kassel

40212

Privatpraxis Dr. Hilton & Partner, Düsseldorf

70006

Coleman Center for Cosmetic Dermatologic Surgery, Metairie

77401

Bellaire Dermatology Associates, Bellaire

80333

Studienzentrum Theatiner46, Munich

85308

Advanced Research Associates, Glendale

92663

Eye Research Foundation, Newport Beach

V5Z 4E1

Dr. Shannon Humphrey Inc., Vancouver

V6H 1K9

Project Skin MD, Vancouver

M5R 3N8

Sweat Clinics of Canada, Toronto

L4L 8E2

Bertucci MedSpa Inc., Woodbridge

SK8 2BD

Saleh Aesthetic Clinic Ltd., Cheadle

W1G 7JE

Cranley Clinic, London

RG24 9DT

Bermuda Practice, Basingstoke

PO18 8AN

Meyer Clinic, Chichester

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) | Biotech Hunter | Biotech Hunter